Form 8-K · Current Report · Filed 2025-04-29
Regeneron Reports First Quarter 2025 Financial Results and Pipeline Updates
Regeneron Pharmaceuticals, Inc. announced its first quarter 2025 financial results, showing total revenues of $3.0 billion, GAAP diluted EPS of $7.27, and non-GAAP diluted EPS of $8.22. Key highlights include a 19% increase in global net sales of Dupixent, regulatory approvals for Dupixent in chronic spontaneous urticaria (CSU) in the U.S. and chronic obstructive pulmonary disease (COPD) in Japan, and FDA acceptance for priority review of EYLEA HD for retinal vein occlusion (RVO) and monthly dosing. Additionally, Lynozyfic was approved in the EU for relapsed/refractory multiple myeloma, and regulatory applications were submitted for Libtayo in adjuvant cutaneous squamous cell carcinoma (CSCC) in the U.S. and EU. Regeneron also announced ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion.
- Filer
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Filed
- Accession
- 0001804220-25-000020
- CIK
- 0000872589
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$610.86
Next session
-2.0%
Since filing
+24.8%
Latest close
$762.63
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from REGN reporting the same item, with the next session's move:
Exhibits (1)
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Never miss another REGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.